FDA, CMS Scramble to Avoid Regulatory Logjam as States Test AI in Clinical Settings (2026 Update)
OVERVIEWFederal regulators are working behind the scenes to prevent a conflict between state-led AI testing initiatives and federal oversight frameworks. As more states launch healthcare AI sandboxes—particularly Utah's expanding program for autonomous prescribing and women's health pilots—the FDA and CMS face pressure to clarify their jurisdictional authority and approval pathways. The core tension: states are moving faster than federal agencies can regulate, creating a patchwork of local AI experiments with inconsistent safety standards. Officials are seeking to coordinate without formally harmonizing rules, using informal channels and pilot programs to test regulatory models. This governance gap reflects a deeper structural problem in U.S. healthcare AI policy: no single entity has clear authority over AI medical devices, and the TEMPO pilot program, while promising, cannot keep pace with state-level innovation velocity.
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.